Inclusion Criteria:

- Age three years and older

- If female and of child bearing potential, documentation of negative pregnancy test
prior to enrollment and, where applicable, use of appropriate, non- estrogen
containing birth control contraceptive regimen whle on study that is to be continued
3 months after discontinuation of everolimus. Use of barrier methods alone will not
constitute an acceptable contraceptive regimen.

- Clinically definite diagnosis of tuberous sclerosis (modified Gomez criteria or
positive genetic test)

- Presence of giant cell astrocytoma as defined by imaging characteristics and serial
increase in size of lesion on 2 or more MRI scans

- Adequate renal function (creatinine < 1.5 mg/dl)

Exclusion Criteria:

- Serious intercurrent medical illness or other uncontrolled medical disease which
could compromise participation in the study

- Significant hematologic or hepatic abnormality

- Continuous requirement for supplemental oxygen

- Intercurrent infection at initiation of oxygen

- Recent surgery (within 2 months of initiation of everolimus)

- Pregnant or lactating women

- Use of an investigational drug within the last 30 days

- Must be adequately recovered from the acute toxicities of any prior therapy

- Clinical evidence of impending herniation or focal neurologic deficit related to the
subject's astrocytoma